Latest News


Study won't sway company to pursue cheaper eye drug option -- South Florida Sun-Sentinel.com

Sun-Sentinel (Fort Lauderdale, Fla.) | 31 minutes ago

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?... (more)


Study outcome won't sway company on eye drug

Los Angeles Times | 5 hours ago

WASHINGTON -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?... (more)


Masimo settles patent suits with NIR and Shaklee

Forbes | 5 hours 54 minutes ago

IRVINE, Calif. - Medical device maker Masimo Corp. said Wednesday it has settled a patent lawsuit brought by Shaklee Corp. and NIR Diagnostics Inc. for an undisclosed amount.... (more)


Grim Reaper Hurts Cell Genesys

Forbes | 5 hours 54 minutes ago

Shares of pharmaceutical maker Cell Genesys tanked on Wednesday after the company announced that it would halt its study of the prostate cancer drug GVAX due to the death of more than 100 participants.... (more)


Cancer Plagues Cell Genesys

Forbes | 5 hours 54 minutes ago

One drug company's pipeline is looking more diseased by the minute.... (more)


SignOnSanDiego.com > News > Business > Biotechnology -- Study outcome won't sway company on eye drug

San Diego Union-Tribune | 6 hours 38 minutes ago

11:18 a.m. August 27, 2008... (more)


Company has little interest in pushing cheaper drug for treating eye disease

Los Angeles Times | 7 hours 1 minute ago

More on LATimes.com Politics |  Science  |  Environment ... (more)


US study outcome will not sway company on eye drug

International Herald Tribune | 7 hours 3 minutes ago

WASHINGTON: What does a company do when there is anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?... (more)


MedQuist Upgrades Dictation App

Health Data Management | 8 hours 27 minutes ago

Medical dictation/transcription vendor MedQuist Inc. has significantly enhanced its PhysAssist dictation application.... (more)


South Dakota hospital boosts care with mobile clinical assistants

Healthcare IT News | 9 hours 2 minutes ago

Loading story... RAPID CITY, SD - Rapid City Regional Hospital has implemented 350 mobile clinical assistants throughout its facility to extend the functionality of its MEDITECH client server information system. The clinical assistants were provided by Austin, Texas-based Motion Computing. ... (more)


FDA Clears Test to Help Doctors Manage Heart-Transplant Patients

Wall Street Journal, The | 10 hours 27 minutes ago

The U.S. Food and Drug Administration said Wednesday that it has cleared for marketing XDx Inc.'s AlloMap, a noninvasive test that assists doctors in managing heart-transplant patients post-surgery for potential organ rejection.... (more)


Cell Genesys ends GVAX trial due to patient deaths

Boston Globe, The | 12 hours 23 minutes ago

SAN FRANCISCO—Cell Genesys Inc. said Wednesday it ended a clinical trial of its prostate cancer vaccine GVAX because patients who were treated with the vaccine were dying more frequently than those only given a standard treatment.... (more)


Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment

Wall Street Journal, The | 12 hours 30 minutes ago

Cell Genesys Inc. has ended its clinical trials of its advanced-stage prostate-cancer treatment after it saw increased death rates compared with another regimen.... (more)


Lucentis: An NHS dilemma

BBC | 12 hours 32 minutes ago

What the controversy over the sight-saving drug Lucentis tells us about the NHS and drugs industry.... (more)




 1  2  3  4  5   Next >

67 Stories  |   RSS Feed



Sign up for AABB SmartBrief



Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of the American Association of Blood Banks and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more

Companies in the news